TSBX (Turnstone Biologics Corp.) יחס שווי שוק לשווי בספרים

Turnstone Biologics costs for developing cancer vaccines are offset by a substantial reserve of equity capital. The market-to-book premium ratio visualizes this resilience, with 0.54 representing the current level of the indicator. Business development relies on robotic drug formula screening and the engineering of unique lytic viruses for solid tumor therapy in US laboratories.

The scale of Turnstone Biologics operations is reflected in the chart of the market-to-book value ratio. This indicator compares the issuer's current market value with its net assets to identify speculative overheating. The calculation is based on dividing the market price of all shares by the value of equity. For Turnstone Biologics (TSBX), this gap is justified by expectations surrounding the TIDAL-01 trials and the development of TIL production. Investors use this metric to assess the premium for future innovations.